Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors
From MaRDI portal
Publication:2233150
Abstract: Phase I dose-finding studies aim at identifying the maximal tolerated dose (MTD). It is not uncommon that several dose-finding studies are conducted, although often with some variation in the administration mode or dose panel. For instance, sorafenib (BAY 43-900) was used as monotherapy in at least 29 phase I trials according to a recent search in clinicaltrials.gov. Since the toxicity may not be directly related to the specific indication, synthesizing the information from several studies might be worthwhile. However, this is rarely done in practice and only a fixed-effect meta-analysis framework was proposed to date. We developed a Bayesian random-effects meta-analysis methodology to pool several phase I trials and suggest the MTD. A curve free hierarchical model on the logistic scale with random effects, accounting for between-trial heterogeneity, is used to model the probability of toxicity across the investigated doses. An Ornstein-Uhlenbeck Gaussian process is adopted for the random effects structure. Prior distributions for the curve free model are based on a latent Gamma process. An extensive simulation study showed good performance of the proposed method also under model deviations. Sharing information between phase I studies can improve the precision of MTD selection, at least when the number of trials is reasonably large.
Recommendations
- Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials
- scientific article; zbMATH DE number 5224906
- A phase I dose-finding study based on polychotomous toxicity responses
- The treatment versus experimentation dilemma in dose finding studies
- A Curve‐Free Method for Phase I Clinical Trials
Cites work
- scientific article; zbMATH DE number 3624599 (Why is no real title available?)
- scientific article; zbMATH DE number 1522714 (Why is no real title available?)
- scientific article; zbMATH DE number 3390139 (Why is no real title available?)
- A weakly informative default prior distribution for logistic and other regression models
- Bayesian data analysis.
- Combining Multiple Comparisons and Modeling Techniques in Dose‐Response Studies
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Covariates and random effects in a Gamma process model with application to degradation and failure
- Determining the Effective Sample Size of a Parametric Prior
- Gaussian processes for machine learning.
- Meta-analysis of two studies in the presence of heterogeneity with applications in rare diseases
- Optimal Bayesian-feasible dose escalation for cancer phase I trials
- Statistical Methods for Dose‐Finding Experiments
- The Brownian movement and stochastic equations
Cited in
(6)- Bayesian aggregation of average data: an application in drug development
- REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors
- MADF
- Dose-finding methods for phase I clinical trials using pharmacokinetics in small populations
- A straightforward meta-analysis approach for oncology phase I dose-finding studies
- Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials
This page was built for publication: Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2233150)
